Meanwhile, strides have recently been made in the treatment of bowel cancer in the United States.
Results of a new trial have been described as “ground-breaking”, as the new drug was found to defeat 100 percent of tumours.
The trial, carried out by Memorial Sloan Kettering Cancer Centre in New York on 12 participants, found the drug dostarlimab was effective at treating bowel cancer.
The drug was given to the patients every three to six months and was developed by GlaxoSmithKline.
This story originally Appeared on Express.co.uk